Health Care & Life Sciences » Biotechnology | Voyager Therapeutics Inc.

Voyager Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
135.00
7,035.00
194,337.00
174,418.00
169,052.00
155,806
Total Accounts Receivable
-
-
411.00
2,303.00
1,452.00
201
Other Current Assets
-
1,323.00
1,146.00
2,065.00
1,286.00
6,474
Total Current Assets
135.00
8,358.00
195,894.00
178,786.00
171,790.00
162,481
Net Property, Plant & Equipment
-
2,804.00
3,234.00
7,893.00
10,283.00
12,771
Total Investments and Advances
-
314.00
30,322.00
2,060.00
1,800.00
1,363
Other Assets
14.00
21.00
7.00
827.00
604.00
414
Total Assets
149.00
11,497.00
229,457.00
189,566.00
184,477.00
177,029
ST Debt & Current Portion LT Debt
2,927.00
-
-
-
-
Accounts Payable
950.00
1,554.00
612.00
550.00
1,020.00
Other Current Liabilities
105.00
920.00
23,319.00
13,252.00
14,877.00
Total Current Liabilities
3,982.00
2,474.00
23,931.00
13,802.00
15,897.00
Long-Term Debt
-
6,305.00
-
-
-
Other Liabilities
-
1,569.00
36,452.00
39,842.00
34,529.00
Total Liabilities
3,982.00
10,348.00
60,383.00
53,644.00
50,426.00
Common Equity (Total)
3,833.00
20,830.00
169,074.00
135,922.00
134,051.00
Total Shareholders' Equity
3,833.00
1,149.00
169,074.00
135,922.00
134,051.00
Total Equity
3,833.00
1,149.00
169,074.00
135,922.00
134,051.00
Liabilities & Shareholders' Equity
149.00
11,497.00
229,457.00
189,566.00
184,477.00
Preferred Stock (Carrying Value)
-
21,979.00
-
-
-

About Voyager Therapeutics

View Profile
Address
75 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.voyagertherapeutics.com
Updated 07/08/2019
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A.